Our Company

Advancing human health by delivering life-changing therapies.

Since its inception in 2004, Tigermed (300347.SZ/3347.HK) has been a trusted clinical research organization that provides full-service for the global biopharmaceutical and medical device industries. We are devoted to serving our customers in their clinical development journey efficiently and cost-effectively. For nineteen years, we have been accelerating the launch of innovative healthcare products with our quality, solutions, teams, experience, and expertise, to advance human health.

Global Employees
10,000+
Global Customers
2,800+
Global Offices and Locations
180+
Chinese Innovative Drugs Involved
92

A Full Service CRO for Healthcare Innovation

Whether you are developing a small molecule or biologic, a vaccine or medical device, we have tailored solutions to move your research forward.

Small Molecule
Biologics
Cell & Gene Therapy
Medical Device
Rare Disease
Vaccine

A Global Presence

Tigermed represents a worldwide network of professional clinical experts. We have more than 100 subsidiaries and 180 offices and sites, with over 10,000 employees across a dozen of countries in Asia Pacific, Europe, North & South America and Africa.

Advance Human Health through Delivery Excellence

Watch Our Corporate Video

Learn more about Our History

Key Milestones of Corporate History

Tigermed

2004

MacroStat

2005

Jiaxing Tigermed

2010

Hangzhou SIMO

Tigermed Hong Kong

2011

IPO in Shenzhen Stock Exchange (300347.SZ)

Fantastic Imaging

2012

Tigermed Taiwan

Bioquick

Tigermed Australia

IntelliPV

Talent

2013

Frontage Lab

Canny Consulting

Clinflash

TigerYeah Capital

2014

DreamCIS

Beijing BDN

2015

Tigermed India

Teddy Laboratory

2016

Tigermed-Jyton

Tigermed Switzerland

2017

OperaCRO

2018

Tigermed America

BRI Pharmaceutical & RMI Laboratories

Frontage IPO in HKSE (1521.HK)

Wuxi Tigermed

Yaxincheng

2019

DreamCIS IPO in Korea

Joint-venture Tigerise

Mosim

Listed in HKEX (3347.HK)

2020

Hainan Tigermed

Global expansion to Latin America, Africa and Middle East

Support of CanSino COVID-19 vaccine

2021

New offices in Europe (UK, Netherlands)

New offices in APAC (Laos, Philippines)

2022

Marti Farm

International HQ in Hong Kong

2023

Customer Recognition is Our

Driving Force

From Our Customers

Best CRO Partnership Award|Merck

Global Supplier Award|Lilly

Outstanding Service Award|Merck

Best Startup Award|Hua Medicine

Best Strategic Collaboration Partner|Sinocelltech

Excellent Teamwork Award|Hutchison

Best Execution Partner Award|Betta Pharma

Best Strategic Partnership Award|Genorbio

Best SMO Company|Cancer Hospital of Peking University

From the Industry

2023 Best Employer Award from LinkedIn

2022 AAA in CNI ESG Rating by Shenzhen Stock Exchange

2022 A ESG Rating from MSCI

2022 Microsoft Best Digital Platform Practice Award

2021 Frost & Sullivan “China Competitive Strategy Leadership”

2021 FORTUNE The Future 50 Companies

2021 China ESG Golden Award – Excellent Social Responsibility

2020 Frost & Sullivan “China CRO Customer Value Leadership”

2019 Forbes Asia's 200 Best Under A Billion Companies